Susquehanna Fundamental Investments’s Supernus Pharmaceuticals SUPN Stock Holding History

Susquehanna Fundamental Investments’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-20,184	Closed	-$661K	–	991
2025 Q1	$661K	Buy	+20,184	New	+$715K	0.01%	783
2024 Q2	–	Sell	-15,899	Closed	-$542K	–	1011
2024 Q1	$542K	Buy	+15,899	New	+$473K	0.03%	453
2023 Q2	–	Sell	-47,212	Closed	-$1.71M	–	856
2023 Q1	$1.71M	Sell	47,212 -8,396	-15%	-$323K	0.04%	416
2022 Q4	$1.98M	Sell	55,608 -4,230	-7%	-$147K	0.03%	484
2022 Q3	$2.03M	Buy	+59,838	New	+$1.95M	0.03%	572
2022 Q1	$581K	Buy	+17,986	New	+$551K	0.01%	1013
2021 Q3	–	Sell	-16,588	Closed	-$511K	–	1884
2021 Q2	$511K	Sell	16,588 -11,866	-42%	-$364K	0.01%	1156
2021 Q1	$745K	Buy	28,454 +15,409	+118%	+$431K	0.01%	999
2020 Q4	$328K	Sell	13,045 -3,455	-21%	-$74.4K	0.01%	1248
2020 Q3	$344K	Buy	16,500 +1,000	+6%	+$22.7K	0.01%	1012
2020 Q2	$368K	Buy	+15,500	New	+$342K	0.02%	691

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Susquehanna Fundamental Investments's SUPN Position: Q2 2025 in Review

Susquehanna Fundamental Investments sold out of Supernus Pharmaceuticals (SUPN) in Q2 2025, closing a stake of 20,184 shares — an estimated $661K sold.

Susquehanna Fundamental Investments first reported a position in SUPN in Q2 2020 and held it in 11 quarters. The position peaked at $2.03M in Q3 2022. 295 funds tracked by Wall St. Rank hold SUPN as of Q2 2025.

Susquehanna Fundamental Investments reported no remaining Supernus Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Susquehanna Fundamental Investments sold 20,184 Supernus Pharmaceuticals shares in Q2 2025, an estimated $661K.
Susquehanna Fundamental Investments first reported a position in Supernus Pharmaceuticals in Q2 2020 and held it in 11 quarters.
Susquehanna Fundamental Investments's Supernus Pharmaceuticals position peaked at $2.03M in Q3 2022.
295 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2025.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2025, filed 14 Aug 2025.